시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 심혈관 치료제 시장 - 규모, 점유율, 성장 분석 : 약제 유형별, 질환 적응증별, 투여 경로별, 유통 채널별, 지역별 산업 예측(2024-2031년)
Cardiovascular Drugs Market Size, Share, Growth Analysis, By Drug Type, By Disease Indication, By Route of Administration, By Distribution Channel, By Region - Industry Forecast 2024-2031
상품코드 : 1619051
리서치사 : SkyQuest
발행일 : 2024년 12월
페이지 정보 : 영문 157 Pages
 라이선스 & 가격 (부가세 별도)
US $ 5,300 ￦ 7,850,000
PDF & Excel (Single User License) help
PDF 및 Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,200 ￦ 9,183,000
PDF & Excel (Multiple User License) help
PDF 및 Excel 보고서를 동일 사업장에서 2-5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 7,100 ￦ 10,516,000
PDF & Excel (Enterprise License) help
PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


한글목차

심혈관 치료제 세계 시장 규모는 2022년에 1,483억 달러로 평가되었고, 2023년 1,543억 달러에서 2031년에는 2,090억 달러로 성장하며, 예측 기간(2024-2031년)의 CAGR은 3.9%로 성장할 전망입니다.

심혈관 질환 치료제 시장은 고혈압 유병률의 상승과 심혈관 질환의 이환율의 상승, 특히 일의 일정이 엄격한 신흥국의 젊은 전문직 사이에서 현저한 성장을 이루고 있습니다. 좌식 라이프스타일과 식생활의 혼란은 심혈관질환률의 상승을 초래하여 관련 의약품의 판매 급증을 촉진하고 있습니다. 선진국에서는 가처분 소득이 높기 때문에 의약품에 대한 액세스가 향상된다는 이점이 있는 한편, 신흥 국가에서는 경제적 제약이나 헬스케어 자원의 인지도의 낮은 과제가 남아 있습니다. 또한, 엄격한 의약품 승인 프로세스와 잠재적인 부작용이 시장 확대의 장벽이 되고 있어 확대하는 심혈관 건강 위기에 대한 대응에 복잡성을 가져오고 있습니다.

목차

소개

조사 방법

주요 요약

시장 역학과 전망

주요 시장 인사이트

심혈관 치료제 시장 규모 : 약제 유형별 및 CAGR(2024-2031년)

심혈관 치료제 시장 규모 : 질환 적응증별 및 CAGR(2024-2031년)

심혈관 치료제 시장 규모 : 투여 경로별 및 CAGR(2024-2031년)

심혈관 치료제 시장 규모 : 유통 채널별 및 CAGR(2024-2031년)

심혈관 치료제 시장 규모 및 CAGR(2024-2031년)

경쟁 정보

주요 기업 프로파일

결론과 권장사항

JHS
영문 목차

영문목차

Global Cardiovascular Drugs Market size was valued at USD 148.3 billion in 2022 and is poised to grow from USD 154.3 billion in 2023 to USD 209.0 billion by 2031, growing at a CAGR of 3.9% during the forecast period (2024-2031).

The cardiovascular drug market is experiencing significant growth driven by increasing hypertension prevalence and the rising incidence of cardiovascular disorders, particularly among young professionals in developing nations with demanding work schedules. Sedentary lifestyles and poor dietary habits contribute to escalating cardiovascular disease rates, prompting a surge in related drug sales. Additionally, the demographic trend shows a disturbing decrease in the age of onset for these disorders, further propelling market demand. While developed countries benefit from higher disposable incomes that enhance drug accessibility, challenges persist in developing regions due to financial constraints and limited awareness of healthcare resources. Moreover, stringent drug approval processes and potential side effects serve as barriers to market expansion, presenting complexities in addressing the growing cardiovascular health crisis.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cardiovascular Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cardiovascular Drugs Market Segmental Analysis

Global Cardiovascular Drugs Market is segmented by Drug Type, Disease Indication, Route of Administration, Distribution Channel and region. Based on Drug Type, the market is segmented into Antihypertensive, Anticoagulants, Antihyperlipidemic, Antiplatelet Drugs, Others. Based on Disease Indication, the market is segmented into Hypertension, Coronary Artery Disease, Hyperlipidaemia, Arrhythmia, Others. Based on Route of Administration, the market is segmented into Oral, Parenteral, Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Cardiovascular Drugs Market

One of the key drivers propelling the Global Cardiovascular Drugs market is the rising prevalence of cardiovascular diseases, which is significantly influenced by sedentary lifestyles. The World Health Organization (WHO) notes that between 60% to 85% of the global population is inactive, with the Centers for Disease Control and Prevention (CDC) reporting approximately 31 million Americans aged 50 and older engaging in minimal physical activity. Additionally, only about 25% of adults in the U.S. meet the recommended levels of exercise. This alarming trend of inactivity contributes to the growing incidence of cardiovascular conditions, subsequently driving demand for cardiovascular medications and treatments.

Restraints in the Global Cardiovascular Drugs Market

One of the key restraints affecting the global cardiovascular drugs market is the shortage of skilled professionals, which hinders effective drug development and patient care. Additionally, the stringent drug approval processes imposed by regulatory authorities can delay the introduction of new therapies, further constraining market growth. Furthermore, the potential side effects associated with certain cardiovascular medications may deter both healthcare providers and patients from utilizing these treatments, leading to limited adoption. These factors collectively create significant challenges that impact the overall expansion and accessibility of cardiovascular drugs in the market.

Market Trends of the Global Cardiovascular Drugs Market

The Global Cardiovascular Drugs market is experiencing robust growth driven by rising obesity and high cholesterol levels, which significantly elevate cardiovascular disease risks. The demand for emergency medications in hospitals highlights a vital growth area, with many patients requiring long-term management for chronic conditions, ensuring consistent revenue streams. The escalating prevalence of hypertension has further fueled the need for blood thinners and antihypertensive drugs. Additionally, increasing life expectancy among the elderly and a concerning rise in cardiovascular diseases among children are propelling market expansion. The chronic nature of hypertensive medications also contributes to sustained demand, reinforcing the market's positive trajectory.

Table of Contents

Introduction

Research Methodology

Executive Summary

Market Dynamics & Outlook

Key Market Insights

Global Cardiovascular Drugs Market Size by Drug Type & CAGR (2024-2031)

Global Cardiovascular Drugs Market Size by Disease Indication & CAGR (2024-2031)

Global Cardiovascular Drugs Market Size by Route of Administration & CAGR (2024-2031)

Global Cardiovascular Drugs Market Size by Distribution Channel & CAGR (2024-2031)

Global Cardiovascular Drugs Market Size & CAGR (2024-2031)

Competitive Intelligence

Key Company Profiles

Conclusion & Recommendation

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기